Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.